Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Trials. 2022 Jun 30;23(1):543. doi: 10.1186/s13063-022-06459-7.
Atherosclerotic cardiovascular disease (ASCVD) remains a major source of mortality in China. Convincing evidence has demonstrated that the reduction of low-density lipoprotein cholesterol (LDL-C) is correlated with lowering ASCVD risk. The efficacy of lifestyle management in lipid levels reduction has been confirmed in numerous studies. However, considering that low compliance to lifestyle management has limited the benefits of lowering lipid levels, cognitive behavior therapy (CBT) is proposed as a solution to improve clinical outcomes. The objective of this trial is to compare the LDL-C outcome in ASCVD patients receiving mobile device-based CBT to a control group, with both groups under standard pharmacological treatments.
This trial is designed as a multicenter, prospective randomized controlled trial with a 6-month follow-up. Mean LDL-C level and the percentage of different LDL-C levels, coefficient of variation of LDL, General Self-Efficacy Scale (GSEs), quality of life index (QL-index), etc., between the two groups at baseline, 1, 3, and 6 months will be measured.
This trial should demonstrate that the implementation of mobile-based CBT intervention will be potentially effective in lowering LDL-C levels in ASCVD patients.
Chinese Clinical Trial Registry ( ChiCTR2100046775 ) [registered: 2021/5/28].
动脉粥样硬化性心血管疾病(ASCVD)仍然是中国主要的死亡原因。有确凿的证据表明,降低低密度脂蛋白胆固醇(LDL-C)与降低 ASCVD 风险相关。许多研究已经证实,生活方式管理在降低血脂水平方面的功效。然而,考虑到生活方式管理的低依从性限制了降低血脂水平的益处,认知行为疗法(CBT)被提出作为改善临床结果的一种解决方案。本试验旨在比较接受基于移动设备的 CBT 的 ASCVD 患者与对照组的 LDL-C 结果,两组均接受标准药物治疗。
本试验设计为一项多中心、前瞻性随机对照试验,随访 6 个月。在基线、1、3 和 6 个月时,测量两组之间的平均 LDL-C 水平和不同 LDL-C 水平的百分比、LDL-C 的变异系数、一般自我效能感量表(GSEs)、生活质量指数(QL-index)等。
本试验应表明,实施基于移动的 CBT 干预措施将有可能有效降低 ASCVD 患者的 LDL-C 水平。
中国临床试验注册中心(ChiCTR2100046775)[注册日期:2021/5/28]。